// App-Quantinova.ai

S126 : GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 'MIDOTARG' PILOT TRIAL

Researchers

Presenter

  • Nigel Russell

Principal Investigators

  • Charlotte Wilhelm-Benartzi

  • Jad Othman

  • Richard Dillon

  • Nicola Potter

  • Jelena Jovanovic

  • Amanda Gilkes

  • Leona M Batten

  • Joanna Canham

  • Emily L Hinson

  • Panos Kottaridis

  • Jamie Cavenagh

  • Claire Arnold

  • Mike Dennis

  • Steve Knapper

Medical Centers

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Haematology Department,Belfast City Hospital,Belfast ,Verenigd Koninkrijk

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • Haematology,Belfast City Hospital,Belfast,Royaume-uni

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Department of Histopathology, St. Bartholomews Hospital, London, United Kingdom

  • Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Haematology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Centre for Trials Research, Cardiff University,Cardiff,Verenigd Koninkrijk

  • School of Medicine,Cardiff Uni

  • Haematology,The Christie NHS Foundation T

  • Department of Medical and Molecular Genetics,K

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • School of Medicine,Cardiff University,Cardiff,Verenigd Koninkrijk

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Haematology,Guy's and

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • Department of Haematology,St Bartholomew's Hospital,London,Vereinigtes Königreich

  • Haematology,The Christie NHS Foundation Trust,Manchester,Vereinigtes Königreich

  • Pathology, University College London Hospitals NHS Foundation Trust, London, UK

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • Department of Medical and Molecular Genetics,Kings College London,London,Royaume-uni

  • Haematology,Belfast City Hospital,Belfast,Regno Unito

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • School of Medicine,Cardiff University,Cardiff,Verenigd Koninkrijk

  • Haematology Department, Belfast City Hospital, Belfast, United Kingdom

  • Department of Medical and Molecular Genetics,Kings College London,London,Vereinigtes Königreich

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • School of Medicine, Cardiff University, Cardiff

  • Rheumatology, University College London

  • Department of Hematology,

  • University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Haematology Department,Belfast City Hospital,Belfast ,Verenigd Koninkrijk

  • Centre for Trials Research, Cardiff University,Cardiff,Royaume-uni

  • Haematology,Belfast City Hospital,Belfast,Regno Unito

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Nucleophosmin 1

Drug/Treatment

  • Daunorubicin

  • Midostaurin

  • Gemtuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved